Theralase(R) 1Q2025 Financial Statements
Toronto, Ontario--(Newsfile Corp. - May 30, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (" Theralase®" or the " Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses has released the Company's unaudited interim consolidated 1Q2025 financial statements (" Financial Statements").
Theralase® will be hosting a conference call on Monday June 9 th, 2025 at 11:00 am ET, which will include a presentation of the financial and operational results for the fiscal quarter ending March 31 st, 2025.
Questions are welcome; however, to ensure we have time to review and properly address them during the call, please send them in advance to mperraton@theralase.com.
An archived version will be available on the website following the conference call.
1 Other represents foreign exchange, interest accretion on lease liabilities and / or interest income
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/2786/253913_18d14c9a14378a83_001full.jpg
Financial Highlights
For the three-month period ended March 31, 2025:
Total revenue was $91,190, compared to $175,554 in Q1 2024, a 48% year-over-year decrease.
Cost of sales was $77,896 (85% of revenue), resulting in a gross margin of $13,294 (15% of revenue), down from $62,114 (35% of revenue) in Q1 2024.
Selling expenses were $68,143, essentially flat compared to $67,552 in the prior year.
Administrative expenses rose to $555,074 from $511,495, a 9% increase driven primarily by professional fees and stock-based compensation.
Research and development expenses were $877,670, up from $756,380, reflecting increased activity to support Study II progress.
Net loss for the period was $1,471,250, compared to $1,266,711 in Q1 2024. This includes $220,538 in non-cash charges such as amortization and stock-based compensation.
Operational Highlights
Private Placements
On March 10, 2025, the Company closed a non-brokered private placement of 1,034,002 units at $0.30 per unit for gross proceeds of $310,201. Each unit consisted of one common share and one non-transferable common share purchase warrant exercisable at $0.45 for five years. Net proceeds were $304,633, after transaction costs.
On April 22, 2025, the Company completed another non-brokered private placement, issuing 1,995,829 units at $0.21 per unit for gross proceeds of $419,124. Each unit included one common share and one non-transferable common share purchase warrant exercisable at $0.32 for five years.
The Company has raised approximately $CAN 6.3 million over the last 2 years through non-brokered private placements in support of its research and development programs. It is currently investigating the use of a full-service investment bank in the United States to advise on potential financings and US listing opportunities. Information on any future financings will be released once available in accordance with applicable securities laws.
Herpes Simplex Virus ("HSV") Treatment Program
Theralase® continues preclinical development of its HSV treatment using non-light activated and light-activated small molecules. The Company is actively working on in-vitro, and in the near future, in-vivo HSV preclinical models to finalize a formulation for optimal dermal penetration to increase patient safety and efficacy. Good Laboratory Practice (" GLP") toxicology studies will commence once a formulation has been finalized. Additional details will be announced as strategic objectives are achieved.
Phase II Bladder Cancer Study Update ("Study II")
82 patients have been treated with the Study Procedure, representing approximately 91% of the total targeted enrollment of 90 evaluable patients.
69 patients have completed their 90-day assessment and are considered evaluable for interim efficacy analysis.
13 additional patients are pending their 90-day assessment and will be included in future efficacy updates once evaluations are complete.
Interim Clinical Results
For the primary endpoint of Study II (Complete Response (" CR") at any point in time) 62% of patients provided the Study Procedure (Study Drug activated by the Study Device) demonstrated a CR. Including patients, who demonstrated an Indeterminate Response (" IR") (negative cystoscopy and positive or suspicious urine cytology), the Total Response ("TR") increases to 70%.
This represents that approximately 2 out of 3 BCG-Unresponsive NMIBC CIS patients treated with Theralase®'s unique Study Procedure are demonstrating complete destruction of their bladder cancer.
For the secondary endpoint of Study II (duration of CR) 42% of treated patients who achieved a CR, maintained their CR response for at least 12 months (450 days from date of Study Procedure).
For the tertiary endpoint of Study II (safety of Study Procedure) 100% (69/69) experienced no Serious Adverse Events (" SAEs") directly related to the Study Drug or Study Device.
Outside of the defined endpoints of Study II, Theralase® has demonstrated a duration of CR at extended time points of 23% at 2 years, 21% at 3 years and 2% at 7 years.
Note: Not all patients have been assessed at these extended time points. As more clinical data is collected, the duration of CR at 2, 3 and 7 years may increase.
Theralase® is on track to complete enrollment in Study II by the summer of 2025.
This will allow the Company to report on 75 patients who have completed Study II in December 2025 and to report on all 90 patients by September 2026.
Upon follow-up of all patients, the Company plans to submit a New Drug Application ("NDA") to Health Canada and the FDA in 4Q2026, with a decision expected by the respective regulatory authorities on a marketing approval in 2027.
As Theralase® completes enrollment in Study II, it is actively searching for commercialization partners for international marketing and sales of Ruvidar®.
To this end, Theralase® is in various stages of initial and advanced discussions with international pharmaceutical companies for various geographical territories concerning:
Licensing of the light-activated Ruvidar® for BCG-Unresponsive NMIBC CIS
Collaborative research focused on investigating light-activated Ruvidar® in the treatment of NMIBC
Collaborative research focused on combining Ruvidar® with other FDA approved drugs
In recent discussions with the FDA, the Company has decided that since Study II is 91% complete, the best course of action is not to pursue Break Through Designation, but to complete Study II and submit the clinical data to the FDA in a formal NDA. At the end of the meeting, the FDA made a comment that they were impressed that the interim clinical data obtained to date was able to be achieved with only one clinical treatment, in the majority of cases.
Ruvidar® has demonstrated 10 years of shelf life, strongly supporting the stability of the molecule and the ability of clinics to store the small molecule for extended periods of time.
Additional Oncology Targets
Theralase® has combined Ruvidar® with transferrin (human glycoprotein) to form Rutherrin®.
Rutherrin® is a strong candidate for the systemic treatment of recurrent, deep seated and/or progressive cancers.
Due to the limitations of using laser light to activate Rutherrin® in deep oncological targets, Theralase® plans to activate Rutherrin® with radiation therapy to increase the "tumour's damage zone" and the effectiveness of Theralase®'s small molecule beyond the reach of light in the body.
Rutherrin®, if clinically proven, will be able to "hunt" and "localize" into cancer cells and when activated by radiation "destroy" them; wherever, they may reside in the body.
The Company expects to complete Good Laboratory Practice toxicology analysis in 4Q2025 to allow commencement of a Phase 0/I/II adaptive clinical study in 1Q2026 for the following indications:
1) Glio Blastoma Multiforme (" GBM") Brain Cancer Treatment
2) Non-Small Cell Lung Cancer (" NSCLC") Treatment
3) Pancreatic Cancer
4) Colorectal Cancer
5) Muscle Invasive Bladder Cancer (" MIBC") Treatment
6) Herpes Simplex Virus (" HSV-1") Topical Treatment for Cold Sore Lesions
For additional information, please refer to the Company's Management's Discussion and Analysis ("MD&A") available at www.sedarplus.ca.
About Ruvidar®:
Ruvidar®(TLD-1433) is a small molecule, able to be activated by light, radiation, sound and/or other drugs, intended for the safe and effective destruction of various cancers, bacteria and viruses.
About Theralase® Technologies Inc.:
Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses.
Additional information is available at www.theralase.com and www.sedarplus.ca
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements:
This news release contains Forward-Looking Statements (" FLS") within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words " may, " should", " will", " anticipates", " believes", " plans", " expects", " estimate", " potential for" and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals.
These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company's small molecule and drug formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict.
Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS.
Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS.
All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS.
For investor information on the Company, please feel to reach out Investor Inquiries - Theralase Technologies.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
33 minutes ago
- CTV News
E-bikes prove popular in Halifax while raising concerns for advocacy group
Bird Canada has brought 300 e-scooters and 200 e-bikes to the Halifax region and says in the first 20 days these devices have received more usage here than when the company first introduced them to other cities. Austin Spademan with Bird Canada even says it's 'record breaking' in terms of initial usage. 'We have already clocked over 24,000 kilometers, which is crazy, and across 3,600 Haligonians have used our service. They are riding an average of 2.36 rides per rider,' says Spademan. 'I think it's great to have more active transportation options,' says Alex Setchell, a Halifax resident. Bird Canada, a Canadian company, has a goal of getting people out of their vehicles. 'Both e-scooters and e-bikes are important tools in the tool kits to give people compelling alternatives to either get straight from where they live to run errands within the community or more importantly connect more with other transit options to completely decouple from completely needing a car to get from point A to point B,' says Spademan. Brynn Budden, public affairs advisor with the Halifax Regional Municipality, says the pilot projects for the e-scooters and e-bikes aim to provide mobility options to residents. 'The system is designed to be affordable and easy to use for both residents and visitors and will complement other existing modes of transportation including Halifax Transit,' says Budden. Bird Canada hopes to grow north of Highway 102 and into Burnside, but for now they are taking things slow. 'We have entered a smaller operating area more, it mainly covers downtown and a few other main areas that are those flex flare zones that I mentioned that we built with the United Way. We are going to grow from here with fleet increases over time as the usage dictates that we could use more vehicles. We are going to do this in partnership with HR,' says Spademan. Anyone can use them but there are rules. 'Definitely should be using the road and all the bike infrastructure, not the sidewalk. In fact, if you are riding on the sidewalk, we can tell,' says Spademan. The devices have sensors that can detect if it's in an area where it's not permitted. They also automatically reduce their speed in designated slow zones. There are consequences for riders who don't follow the guidelines. 'We may give you an email as a rider saying, 'Hey, you know, that's not allowed and you might get in trouble for it so do not be riding on the sidewalks,'' says Spademan. The CNIB Foundation feels those consequences are not enough, and it has concerned for visually-impaired people. 'CNIB has done a lot of advocacies nationwide with e-scooter companies as well as municipal officials and the issues seem to be persisting so I am planning on reaching out to the city to discuss the issue further,' says Shelley Adams, CNIB manager for Atlantic Canada. Tara Niecamp, strategic leadership council co-chair with CNIB, feels not everyone is going to follow the rules. 'For those cases where the policy is not enough, there needs to be really strict penalties, whether that comes down to a financial penalty or revoking of the account for those that don't follow the rules.' says Niecamp. 'For individuals with low vision or who are blind, it's not that easy. Walking, you may not see the device which means that you could trip and fall.' Bird Canada says when they introduced these devices in Ottawa, they worked with groups like the Canadian National Institute for the Blind and have developed a lot of features to make their products less of a potential conflict. 'A lot of that revolves around that parking technology I mentioned, just making sure when our devices are parked that they are out of the public right of way,' says Spademan. The CNIB wants people held accountable. 'The municipality needs to hold the e scooter companies accountable for that and in order to do that the municipality needs to have a system in place where they can track the e-scooters being improperly used,' says Niecamp. 'When you are living with a disability, you are encountering barriers constantly and it is requiring a lot of mental energy even to advocate and report them.' Some Halifax residents say they love the idea, but feel there are a few drawbacks. 'I love this idea of having more transportation options like that aren't vehicles in the city but it was way too expensive and it cost about $15 just to get from the commons down to the waterfront and it was pretty direct and I didn't have to wait a whole lot and also it's not a comfortable ride,' says Shannon Kam. 'The cost goes up pretty quickly if you don't think about it. It will be about $3 a minute sometimes, which is a lot, you know,' says Quinn Marnitz. The municipality admits the project is still in the early stages so components like parking locations and sidewalk detection technologies are still being fine-tuned. E-scooters Hundreds of e-scooters and e-bikes have arrived in Halifax. (Source: Emma Convey/CTV News Atlantic) For more Nova Scotia news, visit our dedicated provincial page
Globe and Mail
39 minutes ago
- Globe and Mail
NS Power CEO, staff questioned over data breach that saw 280,000 customers' data stolen
Nova Scotians have lost trust in the province's largest electric utility, provincial politicians said Wednesday during a heated committee meeting that raised tough questions about the recent ransomware attack on Nova Scotia Power. The cybersecurity breach gave thieves access to personal and financial data belonging to 280,000 ratepayers – about half of the utility's customers. Members of the public accounts committee grilled Nova Scotia Power CEO Peter Gregg and two other senior staff members, asking them how the breach happened and what the company will do to protect ratepayers from financial harm. 'We understand it is very concerning, and we're working hard to address customer issues and to continue to strengthen our systems as we work to restore and rebuild,' Gregg told the committee. Hackers may have stolen up to 140,000 social insurance numbers in NS Power database breach By the time the meeting was over, however, the executives had very little new information to share. 'We have, as far as we understand, 140,000 Nova Scotians who have had their social insurance numbers stolen, and those people are furious,' NDP Leader Claudia Chender told the committee. Gregg said the company, a subsidiary of Halifax-based Emera Inc. EMA-T, identified unusual activity on their servers on April 25, but they later determined the cyber-thieves had accessed the system as early as March 19. The utility has since sent letters to customers informing them the stolen data may include their names, birth dates, e-mail addresses, home addresses, customer account information, driver's licence numbers and, in some cases, bank account numbers and social insurance numbers. The cyberattack affected almost half of the utility's 525,000 customers. Gregg confirmed the company had previously collected social insurance numbers to authenticate customers' identities in cases where multiple customers had the same name, but he said that practice has stopped. The utility now requests only the last three digits of each customer's social insurance number, which is not stored. Still, Chender pressed utility executives to explain why Nova Scotia Power continues to store the full social insurance numbers it had previously collected. But they declined to say, citing an ongoing investigation. 'I don't have an answer for you today,' Gregg said. Chender said Gregg's response was disappointing. 'With stronger safety protocols, Nova Scotians would be protected,' she said. The NDP leader went on to ask how affected ratepayers would be compensated for potential losses. Again, Gregg did not directly answer, saying the utility is offering customers a two-year subscription for credit monitoring, which might be extended. Progressive Conservative member Brian Wong said Nova Scotians deserve better. 'We have Nova Scotians that aren't just scared, they're angry,' he told Gregg. When asked by multiple committee members if Nova Scotia Power would commit to covering the costs of the breach internally rather than handing the bill to ratepayers, Gregg again avoided a direct answer. He said Nova Scotia Power's cybersecurity insurance would likely cover many expenses, but he said the utility doesn't yet know the cost of the breach. 'Until we get further into this investigation and determine total cost, I can't give you a yes or no answer.' Liberal member Derek Mombourquette said Nova Scotia Power's first step toward rebuilding public trust should be promising not to pass on costs to consumers who have long complained about soaring electricity bills and frequent power outages. 'There is no trust with Nova Scotia Power right now,' Mombourquette said after the meeting. 'I don't believe what we heard in the committee today has done any more to reassure the customers.' As the meeting concluded, Chender put forward a motion to request the province's auditor general investigate the breach, which was adopted. Meanwhile, the federal privacy commissioner has already launched an investigation. Philippe Dufresne issued a statement last week saying he started the probe after receiving complaints about the security breach in April.
Globe and Mail
39 minutes ago
- Globe and Mail
Corus Entertainment reverts to single CEO as Troy Reeb steps down
Corus Entertainment Inc. CJR-B-T will once again be led by a sole chief executive officer after one of the two men holding that title stepped down. Co-CEO Troy Reeb is moving on from the company after more than 25 years. John Gossling, who had been co-CEO and chief financial officer, is to take on the top job solo. Gossling will also continue to serve as chief financial officer on an interim basis. Corus says Heather Shaw to retire as executive chair, will remain non-executive chair Lead independent director Mark Hollinger says the switch-up was due to the evolving industry landscape as well as the company's efforts to get its finances in order. Corus owns 30 specialty television services, 36 radio stations and 15 conventional television stations, as well as digital and streaming platforms. In April, the company reported a loss in its second quarter as its revenue fell 10 per cent compared with a year ago.
